Mary Szela has been a member of our board of directors since February 2021. She is a healthcare executive with extensive experience in building healthcare businesses in both C-level and board of director roles. She currently serves as the Chief Executive Officer and President of TriSalus Life Sciences, Inc, an emerging immuno-oncology company targeting immunosuppression in liver metastasis and pancreatic solid tumors.
Ms. Szela has also served as CEO and director of Aegerion Pharmaceuticals, a public company from January 2016 to November 2016. In November 2016, Aegerion merged with QLT Inc. to form Novelion Therapeutics Inc., a public company where Ms. Szela served as Chief Executive Officer and as a member of its board of directors until November 2017. Ms. Szela served as the Chief Executive Officer and a member of the board of directors of of Melinta Therapeutics, Inc., an antibiotic development company, from April 2013 to August 2015. Ms. Szela held ascending management positions at Abbott Laboratories from 1987 to 2012, including President of the company’s U.S. pharmaceutical business from January 2008 to December 2010.
Ms. Szela is currently serving as member of the board of directors of TriSalus Life Sciences, Coherus, Kura Oncology, Alimera Sciences, Omega Therapeutics, and Senda Bioscienes. Ms. Szela previously served as a member of the board of directors of Receptos, Inc., Novo Nordisk, Suneva and Macrolide Pharmaceuticals. She earned an M.B.A. in Business and a B.S. in Nursing, both from the University of Illinois.